Impaired gut microbiota-mediated short-chain fatty acid production precedes morbidity and mortality in people with HIV, 2023, Sereti et al.

Impaired gut microbiota-mediated short-chain fatty acid production precedes morbidity and mortality in people with HIV
Irini Sereti; Myrthe L. Verburgh; Jacob Gifford; Alice Lo; Anders Boyd; Eveline Verheij; Aswin Verhoeven; Ferdinand W.N.M. Wit; Maarten F. Schim van der Loeff; Martin Giera; Neeltje A. Kootstra; Peter Reiss; Ivan Vujkovic-Cvijin

Antiretroviral therapy (ART) has dramatically lengthened lifespan among people with HIV (PWH), but this population experiences heightened rates of inflammation-related comorbidities. HIV-associated inflammation is linked with an altered microbiome; whether such alterations precede inflammation-related comorbidities or occur as their consequence remains unknown.

We find that ART-treated PWH exhibit depletion of gut-resident bacteria that produce short-chain fatty acids (SCFAs)—crucial microbial metabolites with anti-inflammatory properties. Prior reports establish that fecal SCFA concentrations are not depleted in PWH. We find that gut-microbiota-mediated SCFA production capacity is better reflected in serum than in feces and that PWH exhibit reduced serum SCFA, which associates with inflammatory markers. Leveraging stool and serum samples collected prior to comorbidity onset, we find that HIV-specific microbiome alterations precede morbidity and mortality in ART-treated PWH. Among these microbiome alterations, reduced microbiome-mediated conversion of lactate to propionate precedes mortality in PWH.

Thus, gut microbial fiber/lactate conversion to SCFAs may modulate HIV-associated comorbidity risk.


Link | PDF (Cell Reports)